Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) saw a large drop in short interest in July. As of July 31st, there was short interest totaling 47,941 shares, a drop of 45.6% from the July 15th total of 88,087 shares. Approximately 4.7% of the company’s stock are short sold. Based on an average trading volume of 242,713 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

Clearmind Medicine Stock Up 1.6%

Clearmind Medicine stock traded up $0.03 during trading on Monday, hitting $1.89. The stock had a trading volume of 45,763 shares, compared to its average volume of 1,001,865. The stock has a market cap of $1.93 million, a price-to-earnings ratio of -0.01 and a beta of 0.75. Clearmind Medicine has a 1 year low of $1.43 and a 1 year high of $524.00. The stock’s 50 day moving average is $2.23 and its two-hundred day moving average is $6.84.

Clearmind Medicine (NASDAQ:CMND) last issued its earnings results on Monday, June 15th. The company reported ($6.78) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other news, major shareholder Financial Lp Hrt bought 2,159,052 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average cost of $0.15 per share, for a total transaction of $323,857.80. Following the purchase, the insider owned 2,063,266 shares of the company’s stock, valued at approximately $309,489.90. This trade represents a -2,254.04% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 252,615 shares of company stock valued at $117,933 in the last ninety days.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.